Introduction
============

Autoimmune pancreatitis (AIP) is a benign disease that was first reported in 1961. Since the first report, the clinical conditions associated with AIP have gradually been elucidated. Currently, AIP is thought to occur as part of a systemic disease produced by IgG4-positive lymphoplasmacytic infiltration of the involved organs in association with an elevation in the blood level of IgG4 (type 1), or as a primary disease of the pancreas (type 2) ([@B1], [@B2]). Recently, the International Association of Pancreatology presented a set of diagnostic criteria for AIP ([@B3], [@B4]). Importantly, it was previously thought that AIP was not associated with the development of pancreatic cysts ([@B5]). However, there have been a few reports of AIP with an accompanying pancreatic cyst ([@B6]-[@B14]). Moreover, some reports have shown corticosteroid treatment (CST) to be highly effective in treating the accompanying pancreatic cyst ([@B6], [@B10], [@B15]-[@B19]). However, surgical or interventional radiology treatments have occasionally been selected ([@B7], [@B9], [@B18], [@B20], [@B21]).

To date, there has been no consensus on the therapeutic strategy for pancreatic cysts (PCs) that accompany AIP. We herein present 5 cases of AIP-associated PC that were treated by endoscopic ultrasonography-guided pancreatic fluid collection drainage (ESPD) or CST, and describe the therapeutic strategy. We also perform a literature review.

Materials and Methods
=====================

Case 1
------

The patient was a 61-year-old man who had consulted another hospital two years previously with a complaint of abdominal pain. The patient was diagnosed with chronic pancreatitis complicated by a pancreatic tail cyst. The patient was referred to our hospital because of the repeated acute exacerbation of chronic pancreatitis. Abdominal computed tomography (CT) revealed a "sausage-like" diffuse enlargement of the pancreas and a cyst of 60 mm diameter with hemorrhage in the pancreatic tail ([Fig. 1A](#g001){ref-type="fig"}).

![(A) Abdominal CT showed the diffuse enlargement of the pancreas and a cyst (arrow) of 60 mm diameter with hemorrhage in the pancreatic tail. (B, C) ESPD was performed by placing a BFMS and a plastic stent. (D) CT showed a reduction in the size of the pancreatic cyst (arrow) to 40 mm diameter. (E) Another 7-Fr double pigtail stent was re-inserted to the pancreatic cyst through the fistula. (F) CT performed 1 year and 4 months after ESPD showed the complete disappearance of the pancreatic cyst. ESPD: endoscopic ultrasonography-guided pancreatic fluid collection drainage](1349-7235-57-1523-g001){#g001}

The laboratory data revealed a significantly increased serum IgG4 level (1,050 mg/dL; normal range, 4.8-105 mg/dL). Thus, he was diagnosed with AIP complicated by a PC in accordance with the Clinical Diagnostic Criteria for Autoimmune Pancreatitis 2011 ([@B22]). ESPD was performed by placing a biflanged metal stent (BFMS) (AXIOS stent, Boston Scientific, Natick, USA) and a 7-Fr double pigtail stent ([Fig. 1B and C](#g001){ref-type="fig"}). After the placement of the stents, dark red fluid flowed out through the stent and the patient\'s symptoms disappeared immediately. At 6 days after ESPD, follow-up CT showed a reduction in the diameter of the pancreatic cyst to 40 mm ([Fig. 1D](#g001){ref-type="fig"}). The metallic stent undeployed into the stomach; thus, another 7-Fr double pigtail stent was re-inserted ([Fig. 1E](#g001){ref-type="fig"}). The patient was discharged from our hospital on the tenth day after ESPD, and was followed up as an outpatient without CST.

A CT scan performed 1 year and 4 months later showed the complete disappearance of the cyst ([Fig. 1F](#g001){ref-type="fig"}); thereafter, the plastic stent was endoscopically removed. Cystic recurrence was not observed for more than 2 years after ESPD without CST.

Case 2
------

The patient was a 54-year-old man consulted our hospital with complaints of epigastric pain and vomiting after meals. Abdominal CT on admission revealed diffuse enlargement of the pancreas and a cyst of 100 mm diameter with hemorrhage in the pancreatic tail ([Fig. 2A](#g002){ref-type="fig"}). The laboratory data revealed significantly increased levels of serum C-reactive protein (CRP level; 6.5 mg/dL), serum amylase (388 U/L; normal range, 40-122 U/L), and serum IgG4 (290 mg/dL).

Based on these findings and her clinical course, the patient was diagnosed as having AIP complicated by a pancreatic cyst, and thus he was admitted to our hospital. Because of his prolonged symptoms, ESPD was performed by placing a BFMS (AXIOS stent, Boston Scientific) ([Fig. 2B](#g002){ref-type="fig"}). After the placement of the stent, dark red fluid flowed out through the stent and his symptoms disappeared immediately. Magnetic resonance imaging performed 10 days after ESPD showed a reduction in the size of the cyst and the patient was discharged 13 days after ESPD. The patient was started on prednisolone at a dose of 40 mg, daily, for 2 weeks. Thereafter, the dose was tapered by 5 mg per week. The patient\'s serum IgG4 level decreased 11 months after ESPD, and follow-up CT showed the absence of both the cyst and the pancreatic enlargement ([Fig. 2C](#g002){ref-type="fig"}).

![(A) CT showed a cyst (arrow) of 100 mm diameter with hemorrhage in the pancreatic tail. (B) ESPD was performed by placing a BFMS. (C) CT showed the absence of the pancreatic cyst. ESPD: endoscopic ultrasonography-guided pancreatic fluid collection drainage, BFMS: biflanged metal stent](1349-7235-57-1523-g002){#g002}

Case 3
------

The patient was a 63-year-old man who had consulted our hospital 2 years previously with complaints of nausea and upper gastric pain. Abdominal CT revealed the diffuse enlargement of the pancreas and a 40-mm-diameter cyst in the pancreatic tail. The laboratory data revealed a significantly increased serum IgG4 level (706 mg/dL).

The patient was diagnosed with AIP complicated by a pancreatic cyst. He was treated with prednisolone at a dose of 40 mg, daily, for 2 weeks. This resulted in the resolution of the abdominal pain and the swelling of the pancreas; however, the cyst remained in the pancreatic tail. The dose was then tapered by 5 mg per week. Two years after starting CST, and while the patient was being treated with prednisolone (5 mg/day), he visited our hospital with a complaint of left upper abdominal pain. CT revealed the enlargement of the pancreatic cyst to 60 mm diameter ([Fig. 3A](#g003){ref-type="fig"}) and the presence of a lower bile duct stricture. He was diagnosed with recurrent AIP. However, as the bile duct stricture showed no obstructive jaundice and cholangitis, he was treated with a higher dose of prednisolone (25 mg, daily) without biliary drainage.

![(A) CT showed the enlargement of the pancreatic cyst to 60 mm diameter (arrow). (B, C) ESPD was performed by placing a plastic stent. (D) The pancreatic cyst had completely disappeared at 3 months after ESPD. ESPD: endoscopic ultrasonography-guided pancreatic fluid collection drainage](1349-7235-57-1523-g003){#g003}

However, 2 weeks after the treatment, his left upper abdominal pain worsened and his laboratory data showed elevated levels of inflammatory markers, which led to the suspicion of an infected pancreatic cyst. We then performed ESPD for the pancreatic cyst using a 7-Fr double pigtail stent ([Fig. 3B and C](#g003){ref-type="fig"}). After the placement of the stent, dark red fluid flowed out through the stent. After ESPD and intravenous antibiotic therapy, the patient\'s symptom disappeared and he was discharged 7 days after ESPD. The cyst completely disappeared at 3 months after the ESPD ([Fig. 3D](#g003){ref-type="fig"}). There was no recurrence for 6 months, and the patient was treated with prednisolone (5 mg, daily).

Case 4
------

The patient was a 64-year-old man who had visited another hospital one year previously with recurrent acute pancreatitis that had improved with conservative therapy. One month previously, he had visited our hospital with a complaint of left upper abdominal pain. CT showed the diffuse enlargement of the pancreas and a cyst of 130 mm diameter with hemorrhage in the pancreatic tail ([Fig. 4A](#g004){ref-type="fig"}). Moreover, the patient\'s laboratory data revealed a significantly increased serum IgG4 level (706 mg/dL). The patient was diagnosed with AIP complicated by a pancreatic cyst and was referred to our hospital.

![(A) CT showed a pancreatic cyst of 130 mm diameter with hemorrhage in the pancreatic tail (arrow). (B) ESPD was performed by placing a BFMS. (C, D) CT showed a large pancreatic cyst beside the left liver lobe (arrowhead) and multiple small lesions in the liver. (E) ESPD was performed for the recurrent pancreatic cyst by placing a BFMS. (F) CT at 1 month after ESPD showed the absence of both the pancreatic cyst and the multiple liver abscesses. ESPD: endoscopic ultrasonography-guided pancreatic fluid collection drainage, BFMS: biflanged metal stent](1349-7235-57-1523-g004){#g004}

On the fourth day after admission, we performed ESPD for the pancreatic cyst by placing a BFMS (HANARO stent, MI Tech, Seoul, Korea) ([Fig. 4B](#g004){ref-type="fig"}). After the placement of the stent, dark red fluid flowed out through the stent and his symptoms disappeared immediately. The patient was discharged from our hospital 13 days after ESPD. Follow-up CT at 2 months after ESPD showed a reduction in the size of the cyst, which prompted the endoscopic removal of the metallic stent and the placement of a 7-Fr double pigtail stent in the cyst. CST had been planned, however, at 6 months after ESPD he presented to our hospital with complaints of fever and abdominal pain. CT showed a large pancreatic cyst beside the left liver lobe and multiple small lesions in the liver ([Fig. 4C and D](#g004){ref-type="fig"}). Recurrent PC and multiple liver abscesses were diagnosed. ESPD was performed for the recurrent cyst by placing a BFMS (HANARO stent, MI Tech) ([Fig. 4E](#g004){ref-type="fig"}). After stent placement, dark red fluid flowed out through the stent and his symptoms disappeared immediately. Four days after ESPD, follow-up CT revealed a reduction in the size of the cyst located beside the hepatic left lobe. As the pancreatic tail cyst remained small, we placed a 5-Fr nasocystic catheter on the side of the plastic stent for the cyst. The multiple liver abscesses were treated with antibiotics for 4 weeks. Follow-up CT performed one month after ESPD revealed no cysts or multiple liver abscesses ([Fig. 4F](#g004){ref-type="fig"}) and the patient was discharged. At two months after the second ESPD procedure, there was no evidence of recurrence of the PC or liver abscesses, and CST was planned.

Case 5
------

The patient was a 56-year-old woman who had been referred to our hospital with suspected AIP six months previously. Although her serum IgG4 level was normal, abdominal CT showed diffuse pancreatic swelling ([Fig. 5A](#g005){ref-type="fig"}). However, IgG4-positive lymphoplasmacytic infiltration could not be detected by endoscopic ultrasound-fine needle aspiration. Moreover, she refused to undergo endoscopic retrograde pancreatography; thus, she was followed up as an outpatient without a diagnosis of AIP.

![(A) CT showed diffuse pancreatic swelling. (B) CT showed a 25-mm-diameter cyst in the pancreatic tail (arrow). (C) CT showed the complete disappearance of the pancreatic cyst with the resolution of the pancreatic swelling.](1349-7235-57-1523-g005){#g005}

Two days prior to her diagnosis, she visited the presented emergently with nausea and epigastric pain, which had started 2 days previously. CT showed diffuse pancreatic swelling with delayed enhancement, similar to the initial CT findings and a cyst of 25 mm in diameter in the pancreatic tail ([Fig. 5B](#g005){ref-type="fig"}). Her serum IgG4 level was high (184 mg/dL). She was therefore diagnosed as having AIP with a pancreatic cyst.

The patient was admitted to our hospital for closer examination and treatment. She was treated with 40 mg of prednisolone daily for 2 weeks, after which the dose was tapered by 5 mg per week. At three weeks after starting CST, abdominal CT showed the complete disappearance of the cyst with the resolution of pancreatic swelling ([Fig. 5C](#g005){ref-type="fig"}). The patient was treated with corticosteroid maintenance therapy \[prednisolone (5 mg/day)\], and there was no recurrence of PC at 10 months after the onset of disease.

Discussion
==========

AIP has been recognized as a benign disease that promptly responds to CST. It was previously believed that it did not progress to chronic pancreatitis associated with cyst formation or pancreatolithiasis ([@B5]). However, a few cases AIP-associated PC have been reported since 2003 ([@B6]-[@B15], [@B23]).

Some reports have shown that CST was effective in most cases ([@B6], [@B10], [@B15]-[@B19]). However, corticosteroid refractory PCs have also been reported ([@B18], [@B24]). Furthermore, surgical therapy or interventional radiology treatment has occasionally been selected without CST ([@B7], [@B9], [@B18], [@B20], [@B21]). Thus, there is still no consensus on the therapeutic strategy for AIP-associated PC.

There are currently 2 opinions regarding the mechanism of pancreatic cyst formation in AIP. Kubota et al. suggested that PC formation in AIP is associated with left-sided portal hypertension, which is closely associated with the inflammatory process of AIP, which is in a highly active state due to compression by the swollen pancreatic parenchyma and stenosis or occlusion of the peripancreas vascular involvement ([@B18]). On the other hand, Matsubayashi et al. inferred that severe stricture of the main pancreatic duct causes the inflammatory process leading to stasis of the pancreatic juice upstream and resulting in PC formation ([@B19]).

We hypothesize that PCs occur in AIP due to the pancreatic juice stasis caused by severe stricture of the pancreatic duct, as Matsubayashi et al. described. However, we believe that there are 2 processes underlying the development of severe stricture of the pancreatic duct, namely, the inflammation process and the fibrosis process, progressing to chronic pancreatitis.

The highly active inflammation process mainly occurs in the early stage of AIP. Spontaneous remission might occur, or a favorable response to CST might lead to the amelioration of the narrowing of the pancreatic duct and release the pancreatic juice. These induce the resolution of the pancreatic duct and the disappearance of the PC.

On the other hand, AIP has the potential to progress - through fibrosis - to chronic pancreatitis. Murayama et al. reported that the narrowing of both Wirsung\'s and Santorini\'s ducts in AIP might lead to pancreatic juice stasis and stone development, resulting in progression to a long-term chronic state ([@B25]). They also reported that relapse was more frequently observed in cases that progressed to chronic pancreatitis. Kamisawa et al. reported that 92% of AIP patients relapsed within 3 years from the start of CST ([@B26]), suggesting that AIP progressed-due to fibrosis-to chronic pancreatitis during CST.

The clinical characteristics of the reported cases with and without a history of CST are summarized in [Table 1](#t001){ref-type="table"}. The initial treatments were as follows: CST alone (n=13), surgery alone (n=5), ESPD alone (n=3), endoscopic nasopancreatic drainage (ENPD) alone (n=1), and percutaneous cyst drainage (PTCD)+ENPD+CST (n=1). [Table 2](#t002){ref-type="table"} shows the results of CST for PCs accompanying AIP with and without a history of CST. Interestingly, in 8 cases without a history of CST, all PCs disappeared after CST (cases 1, 3, 4, 9, 10, 12, 15, and 23) ([@B6], [@B10], [@B13], [@B15]-[@B17], [@B23]). On the other hand, in 5 cases with a history of CST, a cyst appeared during corticosteroid maintenance therapy (cases 5, 6, 11, 16, 17, and 21) ([@B6], [@B20], [@B24], [@B29]). Although the 2 small cysts (diameters, 17 mm and 25 mm) in case 5 ([@B6]) disappeared after increasing the dose of corticosteroids, the cysts in 4 cases (cases 11, 16, 17, and 21) ([@B20], [@B24], [@B29]) did not disappear after an increase in the dose of corticosteroids; thus, these cysts are referred to as corticosteroid refractory cysts. The second treatments of these cases included surgical treatment in two cases (cases 16 and 17) ([@B24], [@B29]) and ESPD in two cases (cases 11 and 21) ([@B20]). One patient (case 6) ([@B6]) underwent direct surgical treatment; however, the cyst reappeared 2 years later but disappeared after the dose of corticosteroids was increased; thus, all of the patients with corticosteroid refractory PCs received corticosteroid maintenance treatment. We suggest that in patients with corticosteroid refractory PCs, irreversible chronic fibrotic changes had occurred in the pancreatic duct stricture; thus, CST alone is less likely to be effective.

###### 

Clinical Characteristics of Pancreatic Cyst Accompanying AIP with and without CST History.

  Case   Reference    Age/Sex   Symptom   IgG4        PE         PS   PL    CL           CD (mm)       CM   History of CST   Initial treatment   Result (period)            Second treatment
  ------ ------------ --------- --------- ------- --- ---------- ---- ----- ------------ --------- --- ---- ---------------- ------------------- -------------------------- --------------------
  1      23           63/M      \+        ND          Elevated   D    No    tail         35            U    \-               CST                 Disappearance (120 d)      \-
  2      14           66/M      \+        ND          Elevated   F    No    body-tail    200           U    \-               PTCD+ ENPD+CST      Disappearance              \-
  3      15           47/F      \+        623         Elevated   D    No    body-tail    120           U    \-               CST                 Disappearance (112 d)      \-
  4      6            53/F      \+        227         Elevated   D    No    head         35            U    \-               CST                 Disappearance (60 d)       \-
  5      6            62/M      \+        184         No         D    No    body tail    17            U    +(for 2 y)       CST                 Disappearance (28 days)    \-
                                                                            tail         25            U                                                                    
  6      6            55/M      \+        446         No         D    No    tail         60            U    +(for 3 y)       Surgery             Recurrence 2 years later   CS→Disappearance
  7      7            64/M      \+        ND          Elevated   ND   ND    head         50            M    \-               Surgery             \-                         \-
  8      9            63/M      ND        1,160       Elevated   F    No    tail         45            M    \-               Surgery             \-                         \-
  9      16           66/M      \-        867         No         F    No    tail         50            M    \-               CST                 Disappearance (17 d)       \-
  10     17           51/F      \+        410         No         D    No    body-tail    80            U    \-               CST                 Disappearance (280 d)      \-
  11     20           53/M      \+        29          Elevated   F    Yes   head         45            M    +(for 4 y)       CST                 Fail (120 d)→infection     ESPD→Disappearance
  12     10           47/M      \+        228         Elevated   D    No    head, tail   ND            M    \-               CST                 Disappearance (90 d)       \-
  13     27           79/M      \+        ND          ND         F    No    tail         ND            U    \-               Surgery             \-                         \-
  14     28           76/M      \-        1,260       No         No   No    head         18            M    \-               Surgery             \-                         \-
  15     13           75/M      \+        201         Elevated   F    Yes   tail         37            U    \-               CST                 Disappearance (240 d)      \-
  16     29           48/F      \+        165         No         D    ND    tail         30            U    +(for 7 m)       CST                 Fail (60 d)                Surgery
  17     24           63/M      \+        804         Elevated   D    ND    head         40            U    +(for 1 y)       CST                 Fail (360 d)               Surgery
  18     19           64/M      \+        239         Elevated   F    ND    body         130           U    \-               ENPD                Disappearance              \-
  19     Our case 1   61/M      \+        1,050       No         D    No    tail         60            U    \-               ESPD                Disappearance              \-
  20     Our case 2   54/M      \+        290         Elevated   D    No    body-tail    102           U    \-               ESPD                Disappearance              \-
  21     Our case 3   63/M      \+        706         Elevated   D    No    tail         39            U    +(for 2 y)       CST                 Fail (14 d)→infection      ESPD→Disappearance
  22     Our case 4   64/M      \+        605         Elevated   D    No    Tail         131           U    \-               ESPD                Disappearance              \-
                                                                                                                                                 Another cyst recurrence    ESPD→Disappearance
  23     Our case 5   56/F      \+        184         No         D    No    tail         25            U    \-               CST                 Disappearance (21 d)       \-

AIP: autoimmune pancreatitis, M: male, F: female, ND: not described, PE: pancreatic enzyme, PS: pancreatic swelling, D: diffuse, F: focal, PL: pancreatic lithiasis, CL: cyst location, CD: cyst diameter, CM: cyst morphology, U: unilocular, M: multilocular, CST: corticosteroid treatment, y: year, m: month, d: day, PTCD: percutaneous cyst drainage, ENPD: endoscopic nasopancreatic drainage, ESPD: endoscopic ultrasonography-guided pancreatic fluid collection drainage

###### 

Result of CST for Pancreatic Cyst Accompanying AIP with and without CST History.

                                                   Without CST history   With CST history                        
  ------------------------------------------------ --------------------- --------------------------------------- ------------------------------
  Number of patients                               8                     5                                       
  The mean serum IgG4 level (mg/dL)                359                   430                                     
  Pancreatic swelling (Diffuse/Focal)              6/2                   4/1                                     
  Pancreatic lithiasis (+/-/ND)                    1/7/0                 1/2/2                                   
  Cyst size (mm)                                   25-120                17-60                                   
  Cyst morphology (Unilocular/multilocular)        7/2                   4/1                                     
  The time of corticosteroid maintenance therapy   \-                    7 months-2 years                        
                                                                                                                 
  \<Result of treatment\>                                                                                        
  Initial treatment by CST                         All Disappearance     1 Disappearance                         4 Failure (2 infected cysts)
  \[The period of treatment (day)\]                \[17-280\]            \[28\]                                  \[14-360\]
  Second treatment                                                       All Disappearance (2 ESPD, 2 Surgery)   

CST: corticosteroid treatment, AIP: autoimmune pancreatitis, ND: not described, ESPD: endoscopic ultrasonography-guided pancreatic fluid collection drainage

Although CST was associated with a reduction of the size of the PCs in all of the patients without a history of CST, their symptoms disappeared immediately after CST. In contrast, in the cases of corticosteroid refractory PC, all of the cysts increased in size and 2 cysts were complicated by infection after the dose of corticosteroids was increased. Meanwhile, there were no differences in other factors such as the serum IgG4 level, pancreatic swelling, pancreatic lithiasis, and cyst morphology in PCs accompanying AIP with and without a history of CST, and larger cysts were not always refractory to CST.

Four refractory cases received interventional treatment, namely, surgical treatment (cases 16 and 17) ([@B24], [@B29]) and ESPD (cases 11 and 21) ([@B20]). One case (case 6) ([@B6]) received direct surgical treatment; however, the cyst reappeared 2 years later but disappeared after an increase in the dose of corticosteroids; thus, all of the cases of corticosteroid refractory PC received corticosteroid maintenance treatment. We hypothesize that irreversible chronic fibrotic changes occur in the pancreatic duct stricture of patients with corticosteroid-refractory PCs; thus, the administration of CST alone would be less likely to be effective for such patients.

Among the 5 cases in which surgery was selected as the initial treatment (cases 6, 7, 8, 13, and 14) ([@B6], [@B7], [@B9], [@B27], [@B28]), 2 cases were suspected to involve a cystic neoplasm (cases 7 and 14) ([@B7], [@B28]), in 1 case, the patient\'s physical condition did not improve with conservative medical treatment without CST (case 8) ([@B9]), in 1 case, the patient showed an accompanying splenic infarction (case 13) ([@B27]), and in 1 case, a cyst appeared during corticosteroid maintenance therapy (case 6) ([@B6]). All of the patients who received interventional radiology treatments, which included ESPD alone (cases 19, 20, and 22), ENPD alone (case 18) ([@B19]), and PTCD+ENPD+CST (case 2) ([@B14]), were effectively treated.

We believe that interventional treatments such as surgery, interventional EUS, and endoscopic transpapillary drainage, are valid but should not always be the first choice for AIP-associated PC because PCs were effectively treated in in many patients without a history of CST were effectively treated with CST alone, and this treatment led to the disappearance of the cyst. However, although most of the cystic lesions associated with AIP have been reported as pseudocysts or retention cysts ([@B18]), there are some reports describing an association between AIP and neoplastic lesions, such as intraductal papillary mucinous neoplasms, ([@B30]) and pancreatic cancer ([@B19]). Matsubayashi et al. ([@B19]) reported on cases of AIP-associated atypical PCs, such as multilocular cysts or cysts without an obvious corticosteroid response, accompanied by pancreatic ductal carcinoma. Furthermore, some cohort studies showed the development of pancreatic carcinoma (PC) in 2.1-4.8% ([@B31]-[@B33]) of cases of AIP during 4.1 ([@B33])-6.1 ([@B31]) years of follow-up. Ikeura et al. ([@B32]) and Gupta et al. ([@B33]) concluded that the risk of PC in patients with AIP was elevated to a similar level to that observed in patients with ordinary chronic pancreatitis. Thus, the resection of cystic lesions should be considered in cases in which malignant lesions are strongly suspected based on diagnostic imaging.

On the other hand, EUS-guided drainage, which has become a standard therapy for pancreatic cystic lesions worldwide ([@B34]-[@B39]), is considered to be a minimally invasive therapy and to be more suitable than surgical treatment. Although pancreatic cystic lesions (e.g., PC and walled-off necrosis after ordinary acute pancreatitis) are treated by various EUS-guided drainage techniques (e.g., interventional EUS plus the single transluminal gateway technique (SGT), the multiple transluminal gateway technique, and single transluminal gateway transcystic multiple drainage with or without direct endoscopic necrosectomy) ([@B40]-[@B42]), we believe that SGT alone with the placement of a plastic stent is sufficient treatment for AIP-associated PC AIP because most cases show a unilocular morphology and no necrotic tissues. On the other hand, ESPD using a BFMS for pseudocyst and walled-off necrosis has recently been reported as a useful alternative to using 1 or more plastic stents or a conventional self-expandable biliary metal stent ([@B43], [@B44]). A BFMS may provide better drainage due to its large diameter and the use of a BFMS reduces the procedure time and technical complexity because of the ease of placement. Furthermore Mukai et al. showed that there were no significant differences in the rates of adverse events between patients who received BFMSs and those who received plastic stents ([@B45]). Thus, when a patient with AIP develops a PC with hemorrhage, SGT using a BFMS might be superior to SGT using a plastic stent because a plastic stent has a risk of stent obstruction with a clot. However, the BFMS should be endoscopically retrieved soon after the size of the cavity has decreased because the effects of long-term metal stent placement have not been fully elucidated. With regard to nasocystic catheters, Siddiqui et al. reported that in the case of AIP-associated PC, nasocystic catheters should be placed for irrigation and to facilitate the prompt improvement of the infected WON ([@B46]). Thus, if possible, a nasocystic catheter should have been placed in the remnant cyst in Case 4.

It is also important to analyze the cystic fluid to rule out malignant or premalignant cystic neoplasms when ESPD is performed for pancreatic lesions that are refractory to corticosteroids. Endoscopic transpapillary drainage procedures such as ENPD might be effective, but are associated with a risk of acute pancreatitis and there may also be technical difficulty in inserting a drainage tube because of the diffuse narrowing of the main pancreatic duct, which implies that their indication may be limited.

Conclusion
==========

ESPD is an effective and minimally invasive treatment for a PC accompanying AIP. We proposed a treatment strategy for a AIP-associated PCs. The first line of treatment is CST, particularly in cases of a PC without a history of CST. However, ESPD can be applied for PCs that are refractory to CST. Surgical treatment should be considered in cases in which malignant lesions are difficult to distinguish.
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